메뉴 건너뛰기




Volumn 21, Issue 3, 2003, Pages 299-308

Phase I studies of weekly administration of cytotoxic agents: Implications of a mathematical model

Author keywords

Cancer; Cytotoxic agents; Frequent administration; Mathematical model; Phase I study; Simulation

Indexed keywords

CYTOTOXIC AGENT;

EID: 0345283122     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025464510639     Document Type: Article
Times cited : (6)

References (23)
  • 1
    • 0024452804 scopus 로고
    • Design and analysis of phase I clinical trials
    • Storer BE: Design and analysis of phase I clinical trials. Biometrics 45: 925-937, 1989
    • (1989) Biometrics , vol.45 , pp. 925-937
    • Storer, B.E.1
  • 5
    • 0028055206 scopus 로고
    • Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer
    • Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D: Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12: 241-248, 1994
    • (1994) J Clin Oncol , vol.12 , pp. 241-248
    • Schiller, J.H.1    Storer, B.2    Tutsch, K.3    Arzoomanian, R.4    Alberti, D.5    Feierabend, C.6    Spriggs, D.7
  • 9
    • 0025148278 scopus 로고
    • Continual reassessment method: A practical design for Phase I clinical studies in cancer
    • O'Quigley J, Pepe M, Fisher L: Continual reassessment method: a practical design for Phase I clinical studies in cancer. Biometrics 46: 33-48, 1990
    • (1990) Biometrics , vol.46 , pp. 33-48
    • O'Quigley, J.1    Pepe, M.2    Fisher, L.3
  • 11
    • 0028060511 scopus 로고
    • Practical modification of the continual reassessment method for phase I cancer clinical trials
    • Faries D: Practical modification of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 4: 147-164, 1994
    • (1994) J Biopharm Stat , vol.4 , pp. 147-164
    • Faries, D.1
  • 16
    • 0027715143 scopus 로고
    • Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies
    • Schiller JH, Storer B, Arzoomanian R, Tutsch K, Alberti D, Spriggs D: Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies. Invest New Drugs 11: 291-300, 1993
    • (1993) Invest New Drugs , vol.11 , pp. 291-300
    • Schiller, J.H.1    Storer, B.2    Arzoomanian, R.3    Tutsch, K.4    Alberti, D.5    Spriggs, D.6
  • 20
    • 0029963324 scopus 로고    scopus 로고
    • Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: Usefulness of mathematical modeling to determine maximum-tolerable dose
    • Shepherd FA, Burkes R, Cormier Y, Crump M, Feld R, Strack T, Schulz M: Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematical modeling to determine maximum-tolerable dose. J Clin Oncol 14: 1656-1662, 1996
    • (1996) J Clin Oncol , vol.14 , pp. 1656-1662
    • Shepherd, F.A.1    Burkes, R.2    Cormier, Y.3    Crump, M.4    Feld, R.5    Strack, T.6    Schulz, M.7
  • 23
    • 0027499297 scopus 로고
    • Model-guided determination of maximum tolerated dose in phase I clinical trials: Evidence for increased precision
    • Mick R, Ratain MJ: Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. J Natl Cancer Inst 85: 217-223, 1993
    • (1993) J Natl Cancer Inst , vol.85 , pp. 217-223
    • Mick, R.1    Ratain, M.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.